References for: triple

Full identifier: http://www.w3.org/2000/01/rdf-schema#triple

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
In vitro dexamethasone inhibited tissue inflammation
Eva Zegelaar
2021-07-25T21:48:07.976Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
The MerTK - dependent anti - inflammatory mechanisms of dexamethasone , and the homeostatic function of TAM pathways that maintain RA in remission advocate the therapeutic MerTK agonism to ameliorate the cytokine storm and pneumonitis of severe COVID-19
Eva Zegelaar
2021-07-25T21:48:06.253Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
linoleate and dexamethasone reducing the opportunity for ACE2 interaction
Eva Zegelaar
2021-07-25T21:48:04.785Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
linoleate and dexamethasone stabilize the locked spike conformation
Eva Zegelaar
2021-07-25T21:48:03.393Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
A regimen of hydroxychloroquine , azithromycin , and dexamethasone initiated in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management
Eva Zegelaar
2021-07-25T21:48:01.913Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone , a widely available and inexpensive corticosteroid with anti - inflammatory effects , shown a great promise in reducing mortality rates in COVID-19 patients
Eva Zegelaar
2021-07-25T21:48:00.422Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
oral or intravenous low - dose dexamethasone using in adults with COVID-19 disease who require oxygen or mechanical ventilation
Eva Zegelaar
2021-07-25T21:47:58.637Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Only dexamethasone reduce mortality in severe cases
Eva Zegelaar
2021-07-25T21:47:56.729Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Only dexamethasone supporting a role for inflammation in disease severity
Eva Zegelaar
2021-07-25T21:47:55.281Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Only dexamethasone shown reduce mortality in severe cases, further supporting a role for inflammation in disease severity
Eva Zegelaar
2021-07-25T21:47:53.804Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone considered for COVID-19 therapy
Eva Zegelaar
2021-07-25T21:47:52.320Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
positive data with dexamethasone contributed to an increasing proportion of patients who are surviving without the need for mechanical ventilation
Eva Zegelaar
2021-07-25T21:47:50.799Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone added to cover the possibility of COVID-19
Eva Zegelaar
2021-07-25T21:47:49.295Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Treatment with the recombinant interleukin-1 ( IL)-1 ) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR - based markers of inflammation and contractile dysfunction
Eva Zegelaar
2021-07-25T21:47:47.785Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Use of non - steroidal anti - inflammatories , dexamethasone and prophylactic antibiotics associated with smaller reductions in LOS
Eva Zegelaar
2021-07-25T21:47:46.311Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone and COVID-19 antibody transfusion called convalescent plasma therapy s use
Eva Zegelaar
2021-07-25T21:47:44.864Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs 's off - label use against COVID-19 , such as anti - retroviral drugs ( remdesivir , favipiravir , and lopinavir - ritonavir combination ) , biologics ( tocilizumab ) , antibiotics ( azithromycin ) , antiparasitics ( chloroquine and hydroxychloroquine ) , and corticosteroids ( dexamethasone ) remains the associated clinical neuropsychiatric adverse events
Eva Zegelaar
2021-07-25T21:47:43.303Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
azithromycin , dexamethasone , tocilizumab , sarilumab , famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management
Eva Zegelaar
2021-07-25T21:47:41.859Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone is in male subjects & lt;70 years
Eva Zegelaar
2021-07-25T21:47:40.361Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
p & lt;0 05 ) NNT of dexamethasone vs usual care was 17 3 ( 95%CI 14 9–20 6 ) in subjects & lt;70 years
Eva Zegelaar
2021-07-25T21:47:37.973Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone ) inhibited the process of exocytosis
Eva Zegelaar
2021-07-25T21:47:35.599Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone ) showed "anti - allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"
Eva Zegelaar
2021-07-25T21:47:33.915Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone treatment ( 2.5 mg.kg(-1 ) ) from days 3 - 14 post inoculation has no beneficial effect on acute respiratory distress syndrome( ARDS ) induced by the H5N1 viral infection in mice
Eva Zegelaar
2021-07-25T21:47:32.424Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone ( DEX ) treatment alleviate clinical signs , including weight loss , decreased food intake and inactivity
Eva Zegelaar
2021-07-25T21:47:30.965Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone ( DEX ) treatment improve the mortality ( 17 out of 20 versus 16 out of 20 deaths in the DEX - treated infected group DEX - treated versus The infected group )
Eva Zegelaar
2021-07-25T21:47:29.453Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone suppressed exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo
Eva Zegelaar
2021-07-25T21:47:27.954Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
early use of INTERVENTION Use of intravenous remdesivir and dexamethasone be beneficial in refractory Myasthenia gravis ( MG ) cases even with chronic immunosuppression and severe COVID-19 infection
Eva Zegelaar
2021-07-25T21:47:26.443Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
only two treatments , remdesivir and dexamethasone demonstrated clinical efficacythrough randomized controlled trials ( RCTs ) in seriously ill patients
Eva Zegelaar
2021-07-25T21:47:25.030Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the dexamethasone ranked in the prediction , which was the first reported drug to be able to significantly reduce the death rate of COVID-19 patients receiving respiratory support
Eva Zegelaar
2021-07-25T21:47:23.553Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the dexamethasone was top - ranked in the prediction , which was the first reported drug to be able to significantly reduce the death rate of COVID-19 patients receiving respiratory support
Eva Zegelaar
2021-07-25T21:47:22.100Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone 20 mg intravenously followed by dexamethasone 10 mg intravenously once daily on day 6 - 10
Eva Zegelaar
2021-07-25T21:47:20.598Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19
Eva Zegelaar
2021-07-25T21:47:19.105Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone confer any long - term survival benefit
Eva Zegelaar
2021-07-25T21:47:17.645Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone mitigating short - term PMCs or infectious complications
Eva Zegelaar
2021-07-25T21:47:16.200Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone failed to demonstrate any protective advantage in terms of mitigating short - term PMCs or infectious complications , or to confer any long - term survival benefit
Eva Zegelaar
2021-07-25T21:47:14.721Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone associated with any improvement in median recurrence - free survival ( RFS ) ( 17 vs 17 months ; p = 0.99 ) or overall survival ( OS ) ( 46 vs 43 months ; p = 0.90 )
Eva Zegelaar
2021-07-25T21:47:13.306Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Intraoperative dexamethasone associated with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )
Eva Zegelaar
2021-07-25T21:47:11.776Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Administration of dexamethasone mitigate postoperative nausea and vomiting
Eva Zegelaar
2021-07-25T21:47:10.357Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Administration of dexamethasone to mitigate postoperative nausea and vomiting suggested to improve, after pancreatic ductal adenocarcinoma ( PDAC ) resection
Eva Zegelaar
2021-07-25T21:47:08.856Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone levels were detectable
Eva Zegelaar
2021-07-25T21:47:07.442Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
mortality benefits with dexamethasone seen in patients, with, coronavirus disease
Eva Zegelaar
2021-07-25T21:47:05.979Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
low - dose dexamethasone used Therefore, may, in obese children
Eva Zegelaar
2021-07-25T21:47:04.334Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
mg/2 ml dexamethasone 21 - phosphate administered near operated sites
Eva Zegelaar
2021-07-25T21:47:02.852Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone improves outcomes in patients on mechanical ventilators or on oxygen
Eva Zegelaar
2021-07-25T21:47:01.445Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone or methylprednisolone Further understand the pathogenesis , resemblance and differences of this syndrome with a severe Kawasaki disease ( KD ) , understanding of heart injuiry and early recognition for the need of urgent care
Eva Zegelaar
2021-07-25T21:46:59.912Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone or methylprednisolone Further research needed to understand the pathogenesis , resemblance and differences of this syndrome with a severe Kawasaki disease ( KD ) , understanding of heart injuiry and early recognition for the need of urgent care
Eva Zegelaar
2021-07-25T21:46:58.429Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
pre - emptive scalp infiltration with a steroid ( dexamethasone ) plus a local anesthetic ( ropivacaine ) achieve superior postoperative analgesic effects to a local anesthetic ( ropivacaine ) alone in adult patients undergoing a craniotomy
Eva Zegelaar
2021-07-25T21:46:56.935Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the addition of dexamethasone to local infiltration of analgesia ( LIA ) provide significant analgesic effects
Eva Zegelaar
2021-07-25T21:46:55.489Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the addition of dexamethasone to local infiltration of analgesia ( LIA ) prolong the duration of analgesic effects
Eva Zegelaar
2021-07-25T21:46:53.990Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
CONCLUSION Clear evidence of a beneficial or negative effect of dexamethasone is lacking
Eva Zegelaar
2021-07-25T21:46:52.565Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the efficacy and safety of treatment with dexamethasone in patients evaluate with BACKGROUND Spontaneous intracerebral hemorrhage ( ICH )
Eva Zegelaar
2021-07-25T21:46:51.057Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
a number of corticosteroids , including and especially methylprednisolone and dexamethasone demonstrated remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation
Eva Zegelaar
2021-07-25T21:46:49.621Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
adjunctive treatment of established ARDS caused by the coronavirus disease 2019 ( COVID)-19 ) with intravenous dexamethasone reduce morbidity
Eva Zegelaar
2021-07-25T21:46:48.148Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
adjunctive treatment of established ARDS caused by the coronavirus disease 2019 ( COVID)-19 ) with intravenous dexamethasone change the pulmonary and systemic inflammatory response
Eva Zegelaar
2021-07-25T21:46:45.913Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone therapy initiated On day 6
Eva Zegelaar
2021-07-25T21:46:44.411Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone demonstrate any protective advantage
Eva Zegelaar
2021-07-25T21:46:42.965Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
LABAs and dexamethasone exert synergistic effects that will augment both anti - inflammatory and fibronectin - mediated anticoagulant effects
Eva Zegelaar
2021-07-25T21:46:41.041Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone combining with fast long - acting beta-2 adrenergic agonists ( LABAs ) , such as formoterol and salmeterol
Eva Zegelaar
2021-07-25T21:46:38.448Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
administration of adjunctive dexamethasone with the antibiotics lessens neurologic sequelae
Eva Zegelaar
2021-07-25T21:46:36.961Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone exposure minimize while maintaining control of nausea and emesis
Eva Zegelaar
2021-07-25T21:46:35.465Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Single - day dexamethasone dosing recommended over multi - day dosing for regimens with high emetogenic risk excluding high - dose cisplatin , preferably in combination with palonosetron , netupitant , and olanzapine
Eva Zegelaar
2021-07-25T21:46:33.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the administration of dexamethasone continued In Intervention Group 2, will, for 48 - 72 hours
Eva Zegelaar
2021-07-25T21:46:32.502Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the administration of dexamethasone started In Intervention Group 2, will, "within the first 24 hours time of admission"
Eva Zegelaar
2021-07-25T21:46:31.030Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
early administration of dexamethasone in combination with immunoglobulin ( IV)-IG ) and interferon - beta reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19
Eva Zegelaar
2021-07-25T21:46:29.565Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone - related complications result from using higher doses of dexamethasone
Eva Zegelaar
2021-07-25T21:46:28.097Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
heparin and dexamethasone showed improvement
Eva Zegelaar
2021-07-25T21:46:26.691Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Favipiravir , ciclesonide , dexamethasone , and heparin administered in 106 , 168 , 65 , and 38 patients , respectively , but not remdesivir
Eva Zegelaar
2021-07-25T21:46:25.209Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
The antiviral agent , remdesivir , and the immunomodulator , dexamethasone , and inpatients who require mechanical ventilation receive the immunomodulator , dexamethasone monotherapy
Eva Zegelaar
2021-07-25T21:46:23.789Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
low - dose dexamethasone appears To target the inflammatory cascade
Eva Zegelaar
2021-07-25T21:46:22.302Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
low - dose dexamethasone be in moderate to severe cases and trials with anti - interleukin agents ( e.g. , tocilizumab , anakinra , siltuximab ) and non - steroidal anti - inflammatory drugs
Eva Zegelaar
2021-07-25T21:46:20.879Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
etoposide and dexamethasone A follow - up CT chest revealed evolution of the honeycombing lesions
Eva Zegelaar
2021-07-25T21:46:19.355Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
high dose corticosteroid pulse therapy ( HDCPT ) with either methylprednisolone or dexamethasone be an effective intervention to increase COVID-19 survival rates in patients at risk of developing a COVID-19 hyper - inflammatory response
Eva Zegelaar
2021-07-25T21:46:17.902Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
either methylprednisolone or dexamethasone associated with increased survival in COVID-19 patients at risk of hyper - inflammatory response
Eva Zegelaar
2021-07-25T21:46:16.383Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Remdesivir , dexamethasone , azithromycin , favipiravir , lopinavir / ritonavir , atazanavir , hydroxychloroquine , interferon beta , ribavirin , tocilizumab , anakinra and sarilumab identified as experimental drugs being used in the associated coronavirus disease 2019 ( COVID)-19 ) trials as of November 2020
Eva Zegelaar
2021-07-25T21:46:13.433Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Low - dose dexamethasone therapy is the best therapeutic approach
Eva Zegelaar
2021-07-25T21:46:12.011Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the dexamethasone intracanalicular insert produced comparable ocular comfort , corneal staining
Eva Zegelaar
2021-07-25T21:46:10.495Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
visual acuity outcomes to topical prednisolone acetate the dexamethasone intracanalicular insert is an appropriate means of postoperative symptom control in this quality of life - conscious population
Eva Zegelaar
2021-07-25T21:46:09.024Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone be effective in patients in need of respiratory assistance
Eva Zegelaar
2021-07-25T21:46:07.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the anti - inflammatory corticosteroid dexamethasone taking into consideration underlying medical conditions and COVID-19 disease severity
Eva Zegelaar
2021-07-25T21:46:06.144Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the anti - inflammatory corticosteroid dexamethasone impairing viral clearance
Eva Zegelaar
2021-07-25T21:46:04.643Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the anti - inflammatory corticosteroid dexamethasone inducing hyperglycemia and sodium retention
Eva Zegelaar
2021-07-25T21:46:03.230Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the anti - inflammatory corticosteroid dexamethasone being deleterious for diabetics and hypertensive patients , two major COVID-19 risk groups
Eva Zegelaar
2021-07-25T21:46:01.720Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the anti - inflammatory corticosteroid dexamethasone treatment diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation
Eva Zegelaar
2021-07-25T21:46:00.259Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
the anti - inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation
Eva Zegelaar
2021-07-25T21:45:58.684Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Although the anti - inflammatory corticosteroid dexamethasone 's administration for viral infection managing is controversial is increasing evidence demonstrating that the anti - inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation
Eva Zegelaar
2021-07-25T21:45:57.215Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
A regimen of hydroxychloroquine , azithromycin , and dexamethasone initiated in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management
Eva Zegelaar
2021-07-25T21:45:55.668Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
use of intravenous dexamethasone plus standard care compared with standard care alone
Eva Zegelaar
2021-07-25T21:45:54.242Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator - free days ( days alive and free of mechanical ventilation ) over the first 28 days
Eva Zegelaar
2021-07-25T21:45:52.714Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
intravenous dexamethasone increases the number of ventilator - free days among patients with COVID-19 - associated ARDS
Eva Zegelaar
2021-07-25T21:45:51.262Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
Thirty - three patients ( 21.9 % ) in the dexamethasone group vs 43 ( 29.1 % ) in the standard care group experienced secondary infections
Eva Zegelaar
2021-07-25T21:45:49.773Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir used because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19
Eva Zegelaar
2021-07-25T21:45:48.290Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone ( Dex ) could bind to both the viral and host receptors as a potential drug candidate for COVID-19
Eva Zegelaar
2021-07-25T21:45:46.794Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone ( Dex ) bind to both the viral and host receptors as a potential drug candidate for COVID-19
Eva Zegelaar
2021-07-25T21:45:45.370Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone have a better result in hospitalized patients , especially in low - resources settings
Eva Zegelaar
2021-07-25T21:45:43.881Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine
Eva Zegelaar
2021-07-25T21:45:42.454Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine
Eva Zegelaar
2021-07-25T21:45:40.898Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
multiple alternate dosing of NEPA ( netupitant / palonosetron ) without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting , with a good tolerability profile
Eva Zegelaar
2021-07-25T21:45:39.442Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
only dexamethasone and remdesivir be effective
Eva Zegelaar
2021-07-25T21:45:37.960Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
only dexamethasone and remdesivir shown To date
Eva Zegelaar
2021-07-25T21:45:36.473Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
triple
dexamethasone increased mortality
Eva Zegelaar
2021-07-21T12:01:30.231Z